Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Neprilysin Inhibition With ARNI (LCZ 696) on the Cardiorenal and Humoral Response to Acute Saline Volume Expansion in DM With and Without PDD

NCT03744975 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT03744975
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03744975 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Neprilysin Inhibition With ARNI (LCZ 696) on the Cardiorenal and Humoral Response to Acute Saline Volume Expansion in DM With and Without PDD
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Completed
Start date
May 1, 2018
Completion date
August 27, 2025
Enrollment
72 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 2, diastolic dysfunction